Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - lonquex
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mpc90b79fb8cf9d2067c35819ca84918df
identifier: http://ema.europa.eu/identifier
/EU/1/13/856/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Lonquex 6 mg solution for injection in pre-filled syringe
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-c90b79fb8cf9d2067c35819ca84918df
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/13/856/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - lonquex
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
What Lonquex is Lonquex contains the active substance lipegfilgrastim. Lipegfilgrastim is a long-acting modified protein produced by biotechnology in bacteria called Escherichia coli. It belongs to a group of proteins called cytokines and is similar to a natural protein (granulocyte-colony stimulating factor [G-CSF]) produced by your own body.
What Lonquex is used for Lonquex is used in adults and in children aged 2 years and older.
Your doctor has prescribed Lonquex for you or for your child in order to reduce the duration of a condition called neutropenia (low white blood cell count) and the occurrence of febrile neutropenia (low white blood cell count with a fever). These can be caused by the use of cytotoxic chemotherapy (medicines that destroy rapidly-growing cells).
How Lonquex works Lipegfilgrastim stimulates the bone marrow (the tissue where new blood cells are made) to produce more white blood cells. White blood cells are important as they help your body fight infection. These cells are very sensitive to the effects of chemotherapy which can cause the number of these cells in your body to decrease. If white blood cells fall to a low level, there may not be enough left in the body to fight bacteria and you may have an increased risk of infection.
Do not use Lonquex
Warnings and precautions Talk to your doctor, pharmacist or nurse before using Lonquex:
Your doctor will carry out regular blood tests in order to monitor various blood components and their levels. Your doctor will also check your or your child`s urine regularly as other medicines similar to this one (e.g. other granulocyte colony stimulating factors such as filgrastim, lenograstim or pegfilgrastim) can possibly harm the tiny filters inside your kidneys (glomerulonephritis; see section 4. Possible side effects ).
Tell your doctor if you or your child are being treated for breast or lung cancer in combination with chemotherapy and/or radiation therapy and experience symptoms such as tiredness, fever, and easy bruising or bleeding. These symptoms could be a consequence of a precancerous blood condition called myelodysplastic syndrome (MDS) or of a blood cancer called acute myeloid leukaemia (AML) which have been associated with another medicine like this one (pegfilgrastim of the group of G-CSFs).
Inflammation of the aorta (the large blood vessel which transports blood from the heart to the body) has been reported rarely with other medicines like this one (e.g. filgrastim, lenograstim or pegfilgrastim of the group of G-CSFs). The symptoms can include fever, abdominal pain, malaise, back pain and increased inflammatory markers. Tell your doctor if you experience these symptoms.
Children and adolescents Lonquex is not recommended for children younger than 2 years of age.
Other medicines and Lonquex Tell your doctor or pharmacist if you or your child are using, have recently used or might use any other medicines.
Pregnancy and breast-feeding Lonquex has not been tested in pregnant women. It is important to tell your doctor if you are pregnant, think you may be pregnant or are planning to have a baby, as the doctor may decide that you should not use this medicine.
It is unknown whether the active substance in this medicine passes into the breast milk. You should therefore interrupt breast-feeding during treatment.
Driving and using machines Lonquex has no or negligible influence on your ability to drive and use machines.
Lonquex contains sorbitol This medicine contains 30 mg sorbitol in each pre-filled syringe.
Lonquex contains sodium This medicine contains less than 1 mmol sodium (23 mg) per pre-filled syringe, that is to say essentially sodium-free .
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
What the recommended dose is The recommended dose is one pre-filled syringe (6 mg lipegfilgrastim) once per chemotherapy cycle.
The pre-filled syringe is only suitable for adults or for children weighing 45 kg and more.
Lonquex is also available in a vial presentation for children weighing less than 45 kg. The recommended dose will be based on their body weight and the adequate dose will be given by a doctor or a nurse.
When to use Lonquex The Lonquex dose will normally be injected approximately 24 hours after the last dose of chemotherapy at the end of each chemotherapy cycle.
How are the injections given? This medicine is given as an injection using a pre-filled syringe. The injection is given into the tissue just under the skin (subcutaneous injection).
Your doctor may suggest that you learn how to inject yourself with this medicine or how to give the injection to your child. Your doctor or nurse will give you instructions on how to do this. Do not attempt to give Lonquex to yourself or to your child without this training. Information required for using the pre-filled syringe can be found under Information for injecting yourself or your child . Proper treatment of your or of your child s disease, however, requires close and constant co-operation with your doctor.
Information for injecting yourself or your child
This section contains information on how to give yourself or your child an injection of Lonquex under the skin. It is important that you do not try to give yourself or your child the injection unless you have received special training from your doctor or nurse. If you are not sure about giving yourself or your child the injection or you have any questions, please ask your doctor or nurse for help.
How Lonquex is used You will need to give yourself or your child the injection into the tissue just under the skin. This is known as a subcutaneous injection.
Equipment that you need To give yourself or your child an injection into the tissue under the skin you will need:
What you should do before the injection
1
Where the injection should be given The most suitable places for the injection are:
2
If someone else is injecting you or if you are injecting your child, the following places can also be used:
3 4
How to prepare for the injection Before you give yourself or your child a Lonquex injection, you must do the following:
5 6
7
How you should inject yourself or your child
8 9
Remember If you have any problems, please ask your doctor or nurse for help and advice.
Disposing of used syringes
Information for injecting yourself or your child
This section contains information on how to give yourself or your child an injection of Lonquex under the skin. It is important that you do not try to give yourself or your child the injection unless you have received special training from your doctor or nurse. If you are not sure about giving yourself the injection or you have any questions, please ask your doctor or nurse for help.
How Lonquex is used You will need to give yourself or your child the injection into the tissue just under the skin. This is known as a subcutaneous injection.
Equipment that you need To give yourself or your child an injection into the tissue under the skin you will need:
What you should do before the injection
let the pre-filled syringe stand for 30 minutes to reach room temperature (not above
25 C) or
hold the pre-filled syringe gently in your hand for a few minutes.
Do not warm Lonquex in any other way (for example, do not warm it in a microwave or in hot water). 7. Do not remove the needle cover from the syringe until you are ready to inject. 8. Find a comfortable, well-lit place. Put everything you need within easy reach (the Lonquex pre-filled syringe, an alcohol wipe and a piece of gauze bandage or a sterile gauze swab). 9. Wash your hands thoroughly.
1
Where the injection should be given The most suitable places for the injection are:
2
If someone else is injecting you or if you are injecting your child, the following places can also be used:
3 4
How to prepare for the injection Before you give yourself or your child a Lonquex injection, you must do the following:
5 6
7
How you should inject yourself or your child
8 9 Remember If you have any problems, please ask your doctor or nurse for help and advice.
If you use more Lonquex than you should If you use more Lonquex than you should, talk to your doctor.
If you forget to use Lonquex If you have missed an injection, contact your doctor to discuss when you should inject the next dose.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Most serious side effects
Other side effects
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Not known (frequency cannot be estimated from the available data):
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the outer carton and on the label of the pre-filled syringe after EXP. The expiry date refers to the last day of that month.
Store in a refrigerator (2 C 8 C).
Do not freeze.
Keep the pre-filled syringe in the outer carton, in order to protect from light.
Lonquex may be removed from the refrigerator and stored below 25 C for a maximum single period of up to 7 days. Once removed from the refrigerator, the medicine must be used within this period or disposed of.
Do not use this medicine if you notice that it is cloudy or there are particles in it.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Lonquex contains
What Lonquex looks like and contents of the pack Lonquex is a solution for injection (injection) in pre-filled syringe with a fixed injection needle in a blister. Lonquex is a clear and colourless solution. If there are particles in it or if it is cloudy, you must not use it.
Each pre-filled syringe contains 0.6 ml solution.
Lonquex is available in packs containing 1 and 4 pre-filled syringes with safety device or 1 pre-filled syringe without safety device.
Not all pack sizes may be marketed.
Marketing Authorisation Holder Teva B.V. Swensweg 5 2031 GA Haarlem Netherlands
Manufacturer Teva Biotech GmbH Dornierstra e 89079 Ulm Germany
Merckle GmbH, Graf-Arco-Stra e 3 89079 Ulm Germany
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien Teva Pharma Belgium N.V./S.A./AG T l/Tel: +32 38207Lietuva UAB Teva Baltics Tel: +370 52660
Te : +359 24899Luxembourg/Luxemburg Teva Pharma Belgium N.V./S.A./AG Belgique/Belgien T l/Tel: +32 38207 esk republika Teva Pharmaceuticals CR, s.r.o. Tel: +420 251007Magyarorsz g Teva Gy gyszergy r Zrt. Tel: +36 12886Danmark Teva Denmark A/S Tlf: +45 44985Malta Teva Pharmaceuticals Ireland L-Irlanda Tel: +44 2075407Deutschland TEVA GmbH Tel: +49 73140Nederland Teva Nederland B.V. Tel: +31 8000228Eesti UAB Teva Baltics Eesti filiaal Tel: +372 6610Norge Teva Norway AS Tlf: +47 66775
TEVA HELLAS . . : +30 2118805 sterreich ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1970Espa a Teva Pharma, S.L.U. Tel: +34 913873Polska Teva Pharmaceuticals Polska Sp. z o.o. Tel: +48 223459France Teva Sant
T l: +33 155917Portugal Teva Pharma - Produtos Farmac uticos, Lda. Tel: +351 214767Hrvatska Pliva Hrvatska d.o.o. Tel: +385 13720Rom nia Teva Pharmaceuticals S.R.L. Tel: +40 212306Ireland Teva Pharmaceuticals Ireland Tel: +44 2075407Slovenija Pliva Ljubljana d.o.o. Tel: +386 15890 sland Alvogen ehf. S mi: +354 5222Slovensk republika TEVA Pharmaceuticals Slovakia s.r.o. Tel: +421 257267Italia Suomi/Finland Teva Italia S.r.l. Tel: +39 028917Teva Finland Oy Puh/Tel: +358 201805
TEVA HELLAS . .
: +30 2118805Sverige Teva Sweden AB Tel: +46 42121Latvija UAB Teva Baltics fili le Latvij
Tel: +371 67323United Kingdom (Northern Ireland) Teva Pharmaceuticals Ireland Ireland Tel: +44 2075407This leaflet was last revised in {month YYYY}.
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-c90b79fb8cf9d2067c35819ca84918df
Resource Composition:
Generated Narrative: Composition composition-en-c90b79fb8cf9d2067c35819ca84918df
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/13/856/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - lonquex
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mpc90b79fb8cf9d2067c35819ca84918df
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mpc90b79fb8cf9d2067c35819ca84918df
identifier:
http://ema.europa.eu/identifier
/EU/1/13/856/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Lonquex 6 mg solution for injection in pre-filled syringe
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en